P glycoprotein in human immunodeficiency virus type 1 infection and therapy
- PMID: 15047504
- PMCID: PMC375313
- DOI: 10.1128/AAC.48.4.1073-1081.2004
P glycoprotein in human immunodeficiency virus type 1 infection and therapy
References
-
- Alaoui-Jamali, M. A., R. L. Schecter, Y. M. Rustum, M. G. Centurioni, S. Lehnert, and G. Batist. 1993. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933. J. Pharmacol. Exp. Ther. 264:1299-1304. - PubMed
-
- Ameyaw, M. M., F. Regateiro, T. Li, X. Liu, M. Tariq, A. Mobarek, N. Thornton, G. O. Folayan, J. Githang'a, A. Indalo, D. Ofori-Adjei, D. A. Price-Evans, and H. L. McLeod. 2001. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11:217-221. - PubMed
-
- Andreana, A., S. Aggarwal, S. Gollapudi, D. Wien, T. Tsuruo, and S. Gupta. 1996. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 12:1457-1462. - PubMed
-
- Antonelli, G., O. Turriziani, M. Cianfriglia, E. Riva, G. Dong, A. Fattorossi, and F. Dianzani. 1992. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res. Hum. Retrovir. 8:1839-1844. - PubMed
-
- Barry, M., F. Mulcahy, C. Merry, S. Gibbons, and D. Back. 1999. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin. Pharmacokinet. 36:289-304. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical